Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia
- 10 June 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 97 (10), 1767-1774
- https://doi.org/10.1007/s00277-018-3374-x
Abstract
The present observational study aimed to compare the efficacy of azacitidine (AZA) and intensive chemotherapy (IC) in elderly patients with untreated acute myeloid leukemia (AML), diagnosed according to WHO criteria. In the two groups, we evaluated complete remission (CR), overall survival (OS), and disease-free survival (DFS). The AZA group included 89 patients; median age was 73 years (range 61–80) and median white blood cell count (WBCc) 2.5 × 109/L (range 0.27–83), 45% of the patients had BM blasts ≥ 30%, and 44 (49%) had a secondary AML (sAML). Karyotype was evaluable in 69 patients: 51 (74%) had intermediate-risk abnormalities and 18 (26%) an unfavorable risk karyotype. IC group consisted of 110 patients who received an induction course with mitoxantrone, cytarabine, and etoposide, followed by two consolidation cycles including idarubicin, cytarabine, and etoposide. Median age was 67 years (range 61–78) and median WBCc 8.0 × 109/L (range 0.69–258); 44 (40%) had a sAML. Karyotype was evaluable in 88 patients, 71 (81%) had intermediate risk, and 17 (19%) unfavorable risk karyotype. To minimize the effects of treatment selection bias, adjustments were made using the propensity-score matching method, which yielded 74 patient pairs. CR rate was significantly higher in IC vs AZA group (73 vs 25%, respectively) (p < 0.0001), but the 3-year OS rates and median OS were not significantly different (21.6 vs 11% and 15.8 vs 13 months, respectively). Our analysis suggests similar outcomes with AZA compared to IC. Controlled, randomized clinical trials are warranted to confirm this conclusion.Keywords
This publication has 31 references indexed in Scilit:
- Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysJournal of Clinical Oncology, 2017
- Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Hematological Oncology, 2013
- Survival for older patients with acute myeloid leukemia: a population-based studyHaematologica, 2012
- Acute myeloid leukemia in the real world: why population-based registries are neededBlood, 2012
- Treatment of Unfit Patients With Acute Myeloid Leukemia: A Still Open Clinical ChallengeClinical Lymphoma Myeloma and Leukemia, 2011
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood, 2010
- Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-BBlood, 2006
- Age and acute myeloid leukemiaBlood, 2006
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 1999
- On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.Journal of Clinical Oncology, 1989